Development of novel ATMPs (advanced therapy medicinal products) and expansion of their previous areas of application
SaxoCell will significantly improve regional networking in Saxony in the field of cell and gene therapy, integrate further partners and initiatives nationwide and close corresponding gaps in the value chains. In this way, synergy potentials will be raised and realized. In addition, the cluster will massively increase the visibility of the activities of Saxon and nationwide partners in the field of cell and gene therapy – both at the level of research and with regard to the R&D activities of industrial partners. Thus, access to funding will be facilitated and expanded for the players, and structures will be created to accelerate clinical implementation (network of clinical players and cooperation with regulatory authorities). Through these and other activities, SaxoCell will thus significantly increase the attractiveness for investments of national and international companies in this industrial sector and contribute substantially to the development and further strengthening of an innovative cell and gene therapy industry in Saxony and Germany.
Improving the tolerability and efficacy of ATMPs through the latest cell and gene therapy (CGT) technologies
Increasing manufacturing efficiency through automation / artificial intelligence (AI) and standardization
Creation of an innovative preclinical and clinical environment for the optimal development of the industry in Saxony, also through measures of professional education and training
Strengthening regional, national and international technology transfer by attracting investments and innovations from international companies to Saxony